ATAI Research and Charts

ATAI - ATAI Life Sciences NV (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2026-03-20)

Last 3.49	Change ⇓ -0.08 (-2.24%)	Volume 17,827,848
	Open 3.55	High 3.64	Low 3.39

8EMA (Daily) 3.64	40EMA (Daily) 3.80	50EMA (Daily) 3.84	STO (Daily) 23.391	MACD Hist (Daily) -0.036
8EMA (Weekly) 3.658	40EMA (Weekly) 3.70	50EMA (Weekly) 3.56	STO (Weekly) 21.143	MACD Hist (Weekly) -0.033


Company Profile
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.